Skip to main content

Study

Feasibility of Aspirin and/or Vitamin D3 for Men with Prostate Cancer on Active Surveillance with Prolaris® Testing

Early-phase study suggesting aspirin is safe and feasible for men with low-risk prostate cancer under monitoring.

Men's Health
Study Credibility: Medium6.4/10Some supporting evidenceStudy has limitationsUse with caution
PublishedDec 2025Last reviewedFeb 2026
Email this

Summary

In plain language

Early-phase study suggesting aspirin is safe and feasible for men with low-risk prostate cancer under monitoring. While biologically plausible, larger trials are needed to determine if it slows disease progression.

Details

Use the full description to understand the study design, methods, and the limits of the findings.

This feasibility study examined whether low-dose aspirin and/or vitamin D3 could be safely used in men with prostate cancer under active surveillance. The intervention was well-tolerated, with good adherence and no serious safety concerns.

Research Quality Score

Scored February 1, 2026 using rubric v6_2026-02-01.

Assessment

The study provides initial feasibility data on the use of aspirin and vitamin D3 in older adults with prostate cancer. While it is relevant and published in a reputable journal, the study design lacks the rigor of later-phase trials, and there is limited bias control and replication data.

Category Breakdown

CategoryScoreRating
Study design6.0/10
Bias control5.0/10
Statistical methods6.0/10
Reporting completeness7.0/10
Conflicts & funding8.0/10
Replication4.0/10
Relevance to chosen population9.0/10
Journal Reliability7.0/10

Additional Notes

The study is a preliminary investigation, and its findings should be interpreted with caution. Larger, more rigorous trials are necessary to confirm these initial findings.

Take the next step

Build a personalized plan using research-backed studies, conditions, and treatments.